ASH Peak Dialogue | Professors Jing-Zhou Hou & Dehui Zou:Decoding Breakthroughs at the Frontiers of Lymphoma and Sharing New Sino-US Practices

ASH Peak Dialogue | Professors Jing-Zhou Hou & Dehui Zou:Decoding Breakthroughs at the Frontiers of Lymphoma and Sharing New Sino-US Practices

2025.12.27
Lymphoma diagnosis and treatment are entering a phase of accelerated evolution, with breakthrough therapies and innovative research continuously reshaping clinical practice. From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was grandly held in Orlando. At this year’s congress, multidimensional and in-depth innovations emerged across both aggressive lymphoma precision therapy and long-term disease management for indolent lymphomas.
58.4-Month Follow-up Update: KEYNOTE-859 Asian Subgroup Solidifies Pembrolizumab Plus Chemotherapy as First-Line Standard for Gastric Cancer

58.4-Month Follow-up Update: KEYNOTE-859 Asian Subgroup Solidifies Pembrolizumab Plus Chemotherapy as First-Line Standard for Gastric Cancer

2025.12.27
At the recent ESMO-ASIA Congress, Professor Takayuki delivered an in-depth interpretation of the latest follow-up data from the Asian subgroup of the KEYNOTE-859 study. The presentation explored the long-term clinical value of pembrolizumab plus chemotherapy as a first-line treatment for Asian patients with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, providing a comprehensive look at the regimen's durable efficacy over a 5-year timeframe.
ASH China Voice | Professor Cai Zhen: Multidimensional Exploration and Precision Breakthroughs in Multiple Myeloma — From Mechanistic Insights to Therapeutic Innovation 

ASH China Voice | Professor Cai Zhen: Multidimensional Exploration and Precision Breakthroughs in Multiple Myeloma — From Mechanistic Insights to Therapeutic Innovation 

2025.12.25
At the recent Annual Meeting of the American Society of Hematology (ASH), the team led by Professor Cai Zhen and Professor He Jingsong from The First Affiliated Hospital, Zhejiang University School of Medicine, had 12 studies accepted, comprehensively showcasing systematic investigations in multiple myeloma ranging from basic research to clinical translation. These studies focused on key scientific questions including the roots of disease relapse, mechanisms of drug resistance, prognostic evaluation, and therapeutic strategies, forming an integrated evidence chain from mechanistic discovery to clinical application. During the meeting, Hematology Frontier invited Professor Cai Zhen to provide an in-depth interpretation of the team’s research achievements and outline future research plans, offering valuable academic insights to advance the diagnosis and treatment of multiple myeloma.
ASH Voice from China丨Professor Hu Kai: Addressing Clinical Needs and FrontiersMultiple Advances in CAR-T Cell Therapy for Relapsed/Refractory Lymphoma

ASH Voice from China丨Professor Hu Kai: Addressing Clinical Needs and FrontiersMultiple Advances in CAR-T Cell Therapy for Relapsed/Refractory Lymphoma

2025.12.25
The 67th Annual Meeting of the American Society of Hematology (ASH) was held from December 6 to 9, 2025, in Orlando, bringing together the latest global advances in hematology research and clinical practice. At this year’s meeting, the team led by Professor Hu Kai from Beijing Gaobo Hospital presented seven studies focusing on CAR-T cell therapy across different types of relapsed/refractory lymphoma, including B-cell lymphoma, central nervous system lymphoma, T-cell lymphoma, as well as combined strategies involving CAR-T therapy and hematopoietic stem cell transplantation. These studies provide important evidence supporting the further development of individualized treatment strategies. Oncology Frontier – Hematology Frontier invited Professor Hu Kai to provide an in-depth interpretation of these key findings and their clinical significance.